See more : Supreme Infrastructure India Limited (SUPREMEINF.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Universe Pharmaceuticals INC (UPC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Universe Pharmaceuticals INC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fairfax Financial Holdings Limited (FRFXF) Income Statement Analysis – Financial Results
- DynaColor, Inc. (5489.TWO) Income Statement Analysis – Financial Results
- LKP Securities Limited (LKPSEC.BO) Income Statement Analysis – Financial Results
- Ador Multiproducts Limited (ADORMUL.BO) Income Statement Analysis – Financial Results
- Sinmag Equipment Corporation (1580.TWO) Income Statement Analysis – Financial Results
Universe Pharmaceuticals INC (UPC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.universe-pharmacy.com
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 32.31M | 40.14M | 47.98M | 30.70M | 33.23M | 28.51M |
| Cost of Revenue | 21.99M | 18.25M | 22.66M | 16.61M | 19.82M | 15.11M |
| Gross Profit | 10.32M | 21.89M | 25.33M | 14.09M | 13.41M | 13.41M |
| Gross Profit Ratio | 31.93% | 54.53% | 52.78% | 45.90% | 40.35% | 47.03% |
| Research & Development | 4.86M | 7.64M | 5.47M | 583.13K | 618.44K | 789.38K |
| General & Administrative | 2.22M | 1.75M | 3.30M | 1.24M | 713.65K | 704.87K |
| Selling & Marketing | 6.78M | 19.08M | 2.97M | 1.56M | 1.58M | 1.68M |
| SG&A | 9.00M | 20.84M | 6.27M | 2.80M | 2.29M | 2.39M |
| Other Expenses | -17.53K | 430.31K | -80.43K | 365.77K | 445.77K | 5.01K |
| Operating Expenses | 13.84M | 28.91M | 11.74M | 3.74M | 3.36M | 3.65M |
| Cost & Expenses | 35.84M | 47.16M | 34.39M | 20.35M | 23.18M | 18.75M |
| Interest Income | 0.00 | 0.00 | 239.55K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 156.79K | 162.40K | 101.60K | 123.76K | 129.27K | 164.92K |
| Depreciation & Amortization | 508.79K | 533.95K | 446.88K | 410.08K | 418.43K | 452.73K |
| EBITDA | -3.22M | -7.33M | 14.20M | 10.61M | 10.17M | 10.11M |
| EBITDA Ratio | -9.95% | -15.94% | 29.15% | 34.95% | 31.59% | 35.91% |
| Operating Income | -3.53M | -7.02M | 13.59M | 10.25M | 9.75M | 9.66M |
| Operating Income Ratio | -10.92% | -17.49% | 28.32% | 33.39% | 29.35% | 33.87% |
| Total Other Income/Expenses | -322.80K | -545.35K | 88.34K | -151.29K | -99.77K | -138.28K |
| Income Before Tax | -3.85M | -7.98M | 13.68M | 10.10M | 9.65M | 9.52M |
| Income Before Tax Ratio | -11.91% | -19.89% | 28.51% | 32.90% | 29.05% | 33.38% |
| Income Tax Expense | 2.31M | 752.42K | 2.36M | 2.54M | 2.10M | 1.92M |
| Net Income | -6.16M | -8.74M | 11.32M | 7.56M | 7.55M | 7.60M |
| Net Income Ratio | -19.08% | -21.76% | 23.59% | 24.62% | 22.73% | 26.66% |
| EPS | -1.70 | -2.41 | 3.12 | 2.06 | 2.05 | 0.36 |
| EPS Diluted | -1.70 | -2.41 | 3.12 | 2.06 | 2.05 | 0.36 |
| Weighted Avg Shares Out | 3.63M | 3.63M | 3.63M | 3.68M | 3.68M | 21.00M |
| Weighted Avg Shares Out (Dil) | 3.63M | 3.63M | 3.63M | 3.68M | 3.68M | 21.00M |
Oyam North By-election: President Museveni demands action against suspects of ballot stuffing
Former Opposition MPs cross to NRM
UPC Stock Increases Over 7% Intraday: Why It Happened
Universe Pharmaceuticals INC to Announce Unaudited Financial Results for The First Six Months of Fiscal Year 2021 on August 2, 2021
UPC Stock Increases Over 9% Pre-Market: Why It Happened
UPC Stock Increased 28.72% After Hours: Details You Should Know
Sprott Acquires Physical Uranium Fund as Uranium Bear Market Ends
UPC Stock: Why Universe Pharmaceuticals Is Popping Higher Today
Universe Pharmaceuticals Stock Price Increased Over 80% Intraday: Why It Happened
Universe Pharmaceuticals INC Announces Full Exercise of Underwriter's Over-Allotment Option in the Public Offering
Source: https://incomestatements.info
Category: Stock Reports